EGFR and non-small cell lung carcinoma: In 319 patients with EGFR-mutant NSCLC, Cho et al. showed that PD-L1 expression is more prevalent in stage II-IV than in stage I tumors, and in exon 19 deletion than in L858R mutation [74].